differing demographics of vascular parkinsonism and idiopathic parkinson s disease
Download
Skip this Video
Download Presentation
Differing Demographics of Vascular Parkinsonism and Idiopathic Parkinson’s Disease

Loading in 2 Seconds...

play fullscreen
1 / 27

Differing Demographics of Vascular Parkinsonism and Idiopathic Parkinson’s Disease - PowerPoint PPT Presentation


  • 106 Views
  • Uploaded on

Differing Demographics of Vascular Parkinsonism and Idiopathic Parkinson’s Disease. Karthik Sarma MD Resident PGY4 Shreyansh Shah MD and William Ondo MD Dept of Neurology. 14 th April, 2011. 63rd AAN Annual Meeting, Hawaii, 2011. Disclosures. Anand K Sarma, MD Shreyansh D Shah, MD

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' Differing Demographics of Vascular Parkinsonism and Idiopathic Parkinson’s Disease' - jabari


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
differing demographics of vascular parkinsonism and idiopathic parkinson s disease

Differing Demographics of Vascular Parkinsonism and Idiopathic Parkinson’s Disease

Karthik Sarma MD

Resident PGY4

Shreyansh Shah MD and William Ondo MD

Dept of Neurology

14th April, 2011

63rd AAN Annual Meeting, Hawaii, 2011.

disclosures
Disclosures
  • Anand K Sarma, MD
  • Shreyansh D Shah, MD
  • William G Ondo, MD

No disclosures

No disclosures

W. Ondo: Grant Support: Ipsen, Acadia, Bayer, Takeda, Allergan, PSG, HSG, IMPAX

Speaking / Consulting fees: GSK, Allergan, Novartis, Ipsen, TEVA, UCB Pharma, Merz, Lundbeck

vascular parkinsonism
Vascular Parkinsonism
  • Critchley introduced the term in 1929
  • Initially used to describe clinical presentations consisting of…
    • rigidity
    • short-stepping gait
    • fixed facies
    • pyramidal, pseudobulbar signs and cerebellar signs
    • dementia and urinary incontinence
  • Variously referred to as Lower Body Parkinsonism, Arteriosclerotic Pseudo-Parkinsonism, etc.
features of vp
Features of VP
  • Clinical
    • Typically older age of onset
    • Shorter duration of symptoms at presentation
    • Symmetric gait difficulties
    • No rest tremor
  • Imaging
    • Typically chronic small vessel ischemic changes
  • Pathology
    • Absence of Lewy body pathology
imaging
Imaging

Source: BCM imaging database

diagnosing vp
Diagnosing VP
  • No consensus diagnostic criteria available
  • Diagnostic problem in the community especially when non-neurologists and non-movement disorders experts involved in making the diagnosis of Parkinsonian symptoms
  • Several criteria proposed including:
      • Vascular Rating Scale by Winikates and Jankovic
      • Loeb and Gandolfo’s modification of Hachinski score
      • Zijlmans et al criteria for VP
epidemiology of idiopathic pd
Epidemiology of idiopathic PD
  • Age of the patient considered as one of the most important risk factors for development of PD

AGE α RISK of PD

  • Studies have revealed that both Incidence and Prevalence increase with age
incidence of pd
Incidence of PD

Age- and sex-specific average annual incidence rates (per 100,000 person-years) of parkinsonism and its types: Olmsted County, MN, 1976–1990*

Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990.

Bower JH, Maraganore DM, McDonnell SK, Rocca WA.

Neurology. 1999 Apr 12;52(6):1214-20.

question
Question…

Does the misdiagnosis of VP as PD increase the age of onset of PD in epidemiologic studies?

hypothesis
Hypothesis

VP misdiagnosed as PD would cause the average age at symptom onset of PD to increase, altering the age related distribution of PD and hence the epidemiology of PD.

The incidence of PD in the population follows a bell shaped (normal) distribution about a median age of 60 years.

study methods
Study Methods
  • Queried the PDCMDC database for the last 100 consecutive active patients with a diagnosis of VP and PD each.
  • Collected demographic information including age at symptom onset, risk factors, clinical and radiological features.
  • Examined entire database for diagnoses ratio.
  • Calculated how VP would alter epidemiology of PD if labeled as PD.
results
Results
  • No. of VP charts examined: 108
  • Diagnosis changed after initial assignment: 10
  • Total No. of VP considered for analysis: 98
  • The difference of the mean age at symptom onset between VP with and without overt stroke was not significantly different, p = 0.34
results continued
Results continued

*- using Mann Whitney U test

risk factors comparison
Risk Factors: Comparison

* Chi Square test

slide18

Risk Factors: Comparison

* Chi Square test

risk factors
Risk Factors

% Patients

Vascular Risk Factors

age wise distribution of onset of symptoms
Age wise distribution of Onset of Symptoms

% Patients

Age Groups in years

Age Groups in years

caveats of extrapolating the results to predict age of onset for pd
Caveats of extrapolating the results to predict age of onset for “PD”…
  • Sample of 200 patients may not be a representative sample of the database
  • Patient sample and database may not be representative of the population
  • Obvious recruitment bias at a Parkinson’s Disease center
  • Relative occurrence of VP and PD in the population are not similar to database
but if we did extrapolate
But if we did extrapolate…

Does VP misdiagnosed as PD increase the average age at onset of PD?

slide24

Mean Age at Onset for PD would increase from:

57.81 to 59.36

[ 73.59 * 805 / 7742 ] + [ 57.81 * 6937 / 7742 ]

= 59.36

Proportional weighting based on relative occurrence

value of study
Value of study
  • Provides a possible explanation for variability in epidemiology trials of age of onset for PD and more commonly, falsely elevated ages
  • Encouraged future studies such as the ongoing sorting of our entire database
  • Demands a population based incidence study differentiating VP and PD
  • Importance of differentiating the two in the community given disparate pathophysiology, progression, response to treatment, prognosis and importantly, person making the diagnosis.
acknowledgements
Acknowledgements

I would like to thank my friend and colleague, Yogeshwar V Kalkonde for his valuable input and help.

slide27

Questions?

View of Waikiki sunset from my room.

Karthik Sarma; 9th April, 2011.

Thank you!

ad